Abstract:Background Bipolar affective disorder (BPAD) and major depressive disorder (MDD) are two mood disorders whose pathophysiology may involve the purinergic system. Elevated uric acid levels, associated with this system, can impact various behaviors in individuals affected by these conditions. In addition to genetic predisposition, blood uric acid levels can be impacted by various factors, including metabolic syndrome, the consumption of psychoactive medications, and other underlying kidney conditions such as gout. Objective The study aims to investigate the relationship between blood uric acid levels and mental health conditions, specifically BPAD subtypes (manic and depressive) and MDD. The study also examines changes in blood uric acid levels following treatment and evaluates the effectiveness of different treatment approaches in reducing uric acid levels. Methodology To be eligible to participate, individuals must have a confirmed diagnosis of BPAD (manic or depressive type) or MDD, according to the International Classification of Diseases (ICD-10). Blood uric acid levels were measured at both baseline and follow-up assessments. Symptoms were assessed weekly using standardized rating scales (Young Mania Rating Scale (YMRS) and Hamilton Rating Scale for Depression (HAM-D)) until treatment response was achieved, which was defined as a 50% reduction in initial scores on both scales. We used ANOVA to examine the differences among the three patient groups and paired sample t-tests to examine the changes in means before and after treatment conditions. Results A significant positive correlation was found between the severity of illness and serum uric acid levels across all three patient groups: those with BPAD-mania, BPAD-depression, and MDD. Notably, patients with BPAD-mania patients had significantly higher serum uric acid levels (5.2±0.9 mg/dL) compared to those with BPAD-depression (4.8±1.0 mg/dL) and MDD (4.0±1.1 mg/dL). After treatment, all patient groups exhibited a decrease in serum uric acid levels. The reduction in serum uric acid levels was pronounced in all patient groups, with decreases of 3.1±0.8 mg/dL in patients with BPAD-mania, 3.1±0.9 mg/dL in those with BPAD-depression, and 3.5±1.1 mg/dL in those with MDD. The study showed that the reduction in serum uric acid levels was significantly correlated with the severity of illness in patients with BPAD-mania, but not in those with BPAD-depression or MDD. Furthermore, the study found that treatment with lithium carbonate, sodium valproate, or carbamazepine was equally effective in reducing serum uric acid levels, regardless of the mood stabilizer used. Conclusion The study supports that dysfunction in the purine system might play a significant role in the development and progression of BPAD, suggesting that this phenomenon is not solely due to chronicity or medication exposure. This study also introduces a fresh perspective on the underlying biological processes that contribute to the development of BPAD and also sheds light on new treatment regimens targeting uric acid reduction in treating patients with bipolar disorder.

A large-scale study on uric acid-related biomarkers in patients with bipolar disorder

The study on the levels of serum uric acid in patients with bipolar disorder

Latent Profile Analysis of Suicidal Ideation in Chinese Individuals with Bipolar Disorder

Serum uric acid a depression biomarker.

Gut Microbial Signatures Can Discriminate Unipolar from Bipolar Depression

Early Diagnosis of Bipolar Disorder Coming Soon: Application of an Oxidative Stress Injury Biomarker (BIOS) Model.

Development, Validation and Application of the Oxidative Stress Injury Biomarkers Model (BIOS Model) for Predicting Bipolar Disorder

Study on the level and relative factors of serum uric acid in the patients with depressive episodes of bipolar I disorder

Characterizing Unipolar and Bipolar Depression by Alterations in Inflammatory Mediators and the Prefrontal-Limbic Structural Network

Systemic inflammation and oxidative stress markers in patients with unipolar and bipolar depression: A large-scale study

Circulating T-cell Subsets Discrepancy Between Bipolar Disorder and Major Depressive Disorder During Mood Episodes: A Naturalistic, Retrospective Study of 1015 Cases

Non-enzymatic antioxidants, macro-minerals and monocyte/high-density lipoprotein cholesterol ratio among patients with bipolar disorder

Uric Acid as a Biomarker for Mood Disorders: A Comparative Study of Blood Uric Acid Levels Correlating With the Symptom Severity and Treatment Response

High concentrations of serum interleukin-6 and interleukin-8 in patients with bipolar disorder

Olink proteomics analysis uncovers inflammatory proteins in patients with different states of bipolar disorder

Metabolomic analysis to detect urinary molecular changes associated with bipolar depression

Patients with Drug-Naive Bipolar Disorder in Remission after 8 Weeks of Treatment Had Decreased Serum Uric Acid Concentrations.

Oxidative stress parameters and antioxidants in patients with bipolar disorder: Results from a meta‐analysis comparing patients, including stratification by polarity and euthymic status, with healthy controls

Biochemical and Endocrine Parameters for the Discrimination and Calibration of Bipolar Disorder or Major Depressive Disorder

Employing biochemical biomarkers for building decision tree models to predict bipolar disorder from major depressive disorder

Search for serum biomarkers in patients with bipolar disorder and major depressive disorder using metabolome analysis